AI for Longevity Initiatives Recommendation
TOTAL SCORE: 13
Score
A1 (Feasibility increased by continuance of pandemic): +1
A2 (Necessity increased by covid pandemic): +1
A3 (political viability): +1
B1 (Relevance to the specific goal of increasing HALE by 5 years by 2035): +1
B2 (Relevance to general goal of biomedical healthy life extension): +1
C1 (Market readiness applicability): 0
C2 (Project readiness): +1
C3 (Move to market readiness): +1
D1 (Actionability): +1
D2 (Degree of measurability): 0
D3 (Degree of leveraging cross-sector inputs): +1
D4 (Awareness of international context): +1
D5 (Resourcefulness): +1
D6 (Reorganisation): +1
E (Disruptiveness): +1
F (Dividends - does the recommendation aid in social activity and inclusivity?): 0
Point of comparison: The Committee’s document mentions AI in drug discovery explicitly, but omits to mention the link between the two: that AI can accelerate progress by developing biomarkers that are maximally accurate, available, and actionable.
RECOMMENDATION SUMMARY
We recommend that the government prioritise the application of AI for Longevity. Of all the distinct technologies and toolsets driving progress in the global Longevity Industry, the one with the greatest potential to create real-world impact on human Longevity in a short timeframe, and the one with the highest cost-effectiveness ratio, is the application of AI and data science to Longevity. Unfortunately, despite being the pillar with the greatest promise, it happens to be the most underrepresented and underfinanced within the global Longevity Industry.
The are many reasons for the enormous potential of AI in Longevity generally:
1. First, Longevity is unprecedentedly complex, both as a science (dealing with the deepest levels of biology, health and disease) and as an industry (being composed of the intersection of many distinct, individually complex domains of frontier science and technology). AI, data science and mathematics are being applied in the R&D precisely for the purpose of processing data that is too voluminous and complex for humans to address manually - it is the engine not only for neutralizing complexity but also for yielding its power to create new-positive results.
2. Second, with the inevitable increase in distinct data points on the nature of aging, the number of specific biomarkers of aging and Longevity as well as amount of distinct Longevity therapies and technologies, AI will become the only tool for managing this enormous volume of data, both as it applies to P4 Medicine and Precision Health (real-world practical implementation of Longevity technologies) as well as with regard to the core Longevity R&D (which will not reach the level of marked-readiness for a number of years).
3. Third, AI is an industry vertical that is very well funded, with leading nations currently competing to win the global AI race, to develop and secure the most advanced AI technologies and IP, and to capture the highest densities of AI specialists. Ongoing developments in core AI innovation in and of itself are rapidly implementable (being a virtual, digital technology that can be replicated, transmitted near-instantaneously, and utilized at zero material cost once developed), thus being capable of having immediate accelerative impacts on Longevity.
4. Fourth, AI is a self-evolving and self-accelerating technology, in the sense that the latest advances in AI make it easier to develop the next paradigm shift in AI, consequently invoking an exponential effect.
5. Fifth, many technologies and techniques for extending Healthy Human Longevity, for preventive medicine and for maintaining an optimal state of precision health are already innovated, validated and ready for use, however, they lack an infrastructure for scaling them to the masses. This is why we predict that the vast majority of practical, real-world effects in terms of extending healthspans in the next several years will come from existing, validated technologies, thus making it a data aggregation and analysis challenge, rather than a biomedical or biotech R&D problem.
In our opinion, AI for Longevity is the “smart money” sector of the industry which can achieve tremendous results and accelerated timelines in terms of progress in actual, tangible, real-world Healthy Human Longevity, even with modest levels of funding compared to other sectors.
We predict that this is the precise role AI will play in the Longevity space during 1- 2025, i.e., the aggregation, development and deployment of biomarkers of aging, health and Longevity, Preventive Medicine diagnostics and prognostics, Precision Health technologies and therapeutics as well as integrated wealthspan-extending AgeTech and WealthTech solutions for financial wellness across extended periods of Healthy Longevity.
The apex of AI for Human Biomarkers of Longevity, and its most robust and advanced embodiment, will be as the enabling force for creating a so called digital avatar of the full human body, taking into account thousands if not tens of thousands of personalized biomarkers (with at least several hundreds of precise biomarkers of aging and Longevity), both biological as well as psychological and behavioural.
It is clear that AI will soon become not just a complimentary but fundamental tool in developing, refining and applying biomarkers of Human Longevity, serving the foremost catalyst in accelerating progress in this domain, and as acting as the initial trigger in a chain reaction that will lead to rapid progress in the translation of Longevity theory into practice. Indeed, the metaphor of the nuclear chain reaction is not out of place here; in previous reports, Longevity policy proposals, and other materials, we have argued that what the Longevity Industry needs most from national governments is a full-fledged commitment to transform the challenge of aging population into the opportunity of optimized National Healthy Longevity, on the same scale and with the same ambition as the Manhattan Project, and the creation of the atomic bomb. This remains true today, and such a commitment would create just as fundamental and widespread change as did the Manhattan Project, although in a positive rather than negative direction this time.
Score
A1 (Feasibility increased by continuance of pandemic): +1
A2 (Necessity increased by covid pandemic): +1
A3 (political viability): +1
B1 (Relevance to the specific goal of increasing HALE by 5 years by 2035): +1
B2 (Relevance to general goal of biomedical healthy life extension): +1
C1 (Market readiness applicability): 0
C2 (Project readiness): +1
C3 (Move to market readiness): +1
D1 (Actionability): +1
D2 (Degree of measurability): 0
D3 (Degree of leveraging cross-sector inputs): +1
D4 (Awareness of international context): +1
D5 (Resourcefulness): +1
D6 (Reorganisation): +1
E (Disruptiveness): +1
F (Dividends - does the recommendation aid in social activity and inclusivity?): 0
Point of comparison: The Committee’s document mentions AI in drug discovery explicitly, but omits to mention the link between the two: that AI can accelerate progress by developing biomarkers that are maximally accurate, available, and actionable.
RECOMMENDATION SUMMARY
We recommend that the government prioritise the application of AI for Longevity. Of all the distinct technologies and toolsets driving progress in the global Longevity Industry, the one with the greatest potential to create real-world impact on human Longevity in a short timeframe, and the one with the highest cost-effectiveness ratio, is the application of AI and data science to Longevity. Unfortunately, despite being the pillar with the greatest promise, it happens to be the most underrepresented and underfinanced within the global Longevity Industry.
The are many reasons for the enormous potential of AI in Longevity generally:
1. First, Longevity is unprecedentedly complex, both as a science (dealing with the deepest levels of biology, health and disease) and as an industry (being composed of the intersection of many distinct, individually complex domains of frontier science and technology). AI, data science and mathematics are being applied in the R&D precisely for the purpose of processing data that is too voluminous and complex for humans to address manually - it is the engine not only for neutralizing complexity but also for yielding its power to create new-positive results.
2. Second, with the inevitable increase in distinct data points on the nature of aging, the number of specific biomarkers of aging and Longevity as well as amount of distinct Longevity therapies and technologies, AI will become the only tool for managing this enormous volume of data, both as it applies to P4 Medicine and Precision Health (real-world practical implementation of Longevity technologies) as well as with regard to the core Longevity R&D (which will not reach the level of marked-readiness for a number of years).
3. Third, AI is an industry vertical that is very well funded, with leading nations currently competing to win the global AI race, to develop and secure the most advanced AI technologies and IP, and to capture the highest densities of AI specialists. Ongoing developments in core AI innovation in and of itself are rapidly implementable (being a virtual, digital technology that can be replicated, transmitted near-instantaneously, and utilized at zero material cost once developed), thus being capable of having immediate accelerative impacts on Longevity.
4. Fourth, AI is a self-evolving and self-accelerating technology, in the sense that the latest advances in AI make it easier to develop the next paradigm shift in AI, consequently invoking an exponential effect.
5. Fifth, many technologies and techniques for extending Healthy Human Longevity, for preventive medicine and for maintaining an optimal state of precision health are already innovated, validated and ready for use, however, they lack an infrastructure for scaling them to the masses. This is why we predict that the vast majority of practical, real-world effects in terms of extending healthspans in the next several years will come from existing, validated technologies, thus making it a data aggregation and analysis challenge, rather than a biomedical or biotech R&D problem.
In our opinion, AI for Longevity is the “smart money” sector of the industry which can achieve tremendous results and accelerated timelines in terms of progress in actual, tangible, real-world Healthy Human Longevity, even with modest levels of funding compared to other sectors.
We predict that this is the precise role AI will play in the Longevity space during 1- 2025, i.e., the aggregation, development and deployment of biomarkers of aging, health and Longevity, Preventive Medicine diagnostics and prognostics, Precision Health technologies and therapeutics as well as integrated wealthspan-extending AgeTech and WealthTech solutions for financial wellness across extended periods of Healthy Longevity.
The apex of AI for Human Biomarkers of Longevity, and its most robust and advanced embodiment, will be as the enabling force for creating a so called digital avatar of the full human body, taking into account thousands if not tens of thousands of personalized biomarkers (with at least several hundreds of precise biomarkers of aging and Longevity), both biological as well as psychological and behavioural.
It is clear that AI will soon become not just a complimentary but fundamental tool in developing, refining and applying biomarkers of Human Longevity, serving the foremost catalyst in accelerating progress in this domain, and as acting as the initial trigger in a chain reaction that will lead to rapid progress in the translation of Longevity theory into practice. Indeed, the metaphor of the nuclear chain reaction is not out of place here; in previous reports, Longevity policy proposals, and other materials, we have argued that what the Longevity Industry needs most from national governments is a full-fledged commitment to transform the challenge of aging population into the opportunity of optimized National Healthy Longevity, on the same scale and with the same ambition as the Manhattan Project, and the creation of the atomic bomb. This remains true today, and such a commitment would create just as fundamental and widespread change as did the Manhattan Project, although in a positive rather than negative direction this time.